RARE

Ultragenyx Pharmaceutical Inc.

Price

$26.24

return (12m)

-9.89%

p/e

-4.54

p/bv

-9.37

DIVIDEND YIELD

0.00%

RARE price

Ultragenyx Pharmaceutical

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment RARE

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

-8.76%

3 months

10.67%

1 year

-9.89%

2 years

-51.21%

5 years

-67.27%

10 years

0.00%

Asset Comparator

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Fundamentals RARE

Valuation

P/E

-4.54

Sector -4.38

Industry -4.38

P/BV

-9.37

Sector 2.02

Industry 2.02

P/Revenue (PSR)

3.71

Sector -4.40

Industry -4.40

EV/EBITDA

-38.82

Sector -263.09

Industry -263.09

EV/EBIT

-34.32

Sector -702.90

Industry -702.90

P/EBITDA

-5.63

Sector -4.39

Industry -4.39

P/EBIT

-5.26

Sector -4.73

Industry -4.73

P/Total Assets

2.10

Sector 1.49

Industry 1.49

P/Net Current Assets

-2.82

Sector -11.70

Industry -11.70

P/Working Capital

10.43

Sector -3.19

Industry -3.19

EPS

-5.74

Sector -2.14

Industry -2.14

BVPS

-2.78

Sector 1.85

Industry 1.85

Efficiency

Gross Margin

83.08%

Sector 36.74%

Industry 36.74%

EBITDA Margin

-28.50%

Sector -16,244.81%

Industry -16,244.81%

EBIT Margin

-32.24%

Sector -4,202,541.34%

Industry -4,202,541.34%

Operating Margin

-73.64%

Sector -38.22%

Industry -38.22%

Net Profit Margins

-81.70%

Sector -39.69%

Industry -39.69%

Asset Turnover

0.17

Sector 0.03

Industry 0.03

Profitability

ROE

206.33%

Sector -65.14%

Industry -65.14%

ROA

-46.36%

Sector -65.53%

Industry -65.53%

ROIC

-37.27%

Sector -2,103.35%

Industry -2,103.35%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

Sector -

Industry -

Debt

Current Ratio

1.73

Sector 2.90

Industry 2.90

Net Debt / EBITDA

4.79

Sector -6.07

Industry -6.07

Net Debt / EBIT

4.23

Sector -8.26

Industry -8.26

Net Debt / Equity

1.03

Sector -1.07

Industry -1.07

Gross Debt / Equity

0.00

Sector -0.05

Industry -0.05

Equity/Assets

-0.22

Sector 0.41

Industry 0.41

Liabilities/Assets

1.22

Sector 0.39

Industry 0.39

Growth

5Y Revenue CAGR

15.34%

Sector -

Industry -

5Y Earnings CAGR

5.23%

Sector -

Industry -

Fundamentals RARE

DRAG THE FRAME TO SEE MORE DATA

Assets	Price (US$)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
RARE Ultragenyx Pharmaceutical Inc.	$26.24	-11.65%	0.00%	-4.54	-9.37	206.33%	-81.70%
JNJ Johnson & Johnson	$273.41	58.46%	2.02%	29.66	7.34	24.76%	21.48%
PFE Pfizer Inc.	$28.24	21.45%	6.54%	34.62	1.75	5.07%	6.80%
ABBV AbbVie Inc.	$265.97	33.11%	2.73%	70.02	-74.53	-106.44%	9.81%
NVO Novo Nordisk A/S	$46.48	-9.14%	4.09%	11.13	5.91	53.11%	35.32%
MRK Merck & Co. Inc.	$152.20	87.95%	2.45%	106.68	8.06	7.56%	4.77%
AZN AstraZeneca PLC	$164.95	4.92%	2.07%	22.98	4.77	20.74%	17.02%
BMY Bristol-Myers Squibb Company	$67.61	46.95%	3.93%	14.06	5.85	41.59%	18.87%
ZTS Zoetis Inc.	$76.68	-48.52%	2.77%	11.89	9.88	83.10%	27.49%
REGN Regeneron Pharmaceuticals Inc.	$840.84	43.05%	0.45%	19.09	2.61	13.65%	27.86%
AMGN Amgen Inc.	$442.36	55.11%	2.39%	25.30	18.93	74.80%	22.95%
HALO Halozyme Therapeutics Inc.	$107.62	56.06%	0.00%	27.82	80.17	288.14%	24.86%
MCK McKesson Corporation	$853.71	27.85%	0.38%	22.42	-79.15	-352.96%	1.12%
VRTX Vertex Pharmaceuticals Incorporated	$552.06	41.60%	0.00%	29.26	6.36	21.76%	35.00%
CAH Cardinal Health Inc.	$234.85	58.85%	0.88%	31.61	-19.89	-62.92%	0.67%
HRMY Harmony Biosciences Holdings Inc.	$39.93	9.67%	0.00%	12.18	2.21	18.14%	18.89%
BIIB Biogen Inc.	$221.56	63.02%	0.00%	37.04	1.64	4.43%	8.32%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

RARE Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc.

Average Investor10 user rating

4.0 (2 people)

United States

16 years

Founded: 2010

Time since IPO - - year

893

Employees

Ultragenyx Pharmaceutical Inc. (United States) is listed on the Nasdaq and has a market capitalization of $2.66 billion, with shareholders equity totaling $-284.00 million.

The company employs approximately 893 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, Ultragenyx Pharmaceutical Inc. reported $717.21 million in revenue, generating net income of $-585.97 million.

Key financial metrics include a P/E ratio of -4.54, a price-to-book (P/B) ratio of -9.37, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker RARE.

Market cap

$2.66 billion

Net worth

$-284.00 million

$-284,000,000.00

Assets

$1.26 billion

$1,264,000,000.00

Total Shares Outstanding

102.00 million

102,000,000

Average Daily Trading Volume

$2.39 million

$2,394,780.50

Sector

Health Care

Industry

Biotechnology

RARE

RARE revenue and profits

Financial Results RARE

DRAG THE FRAME TO SEE MORE DATA

RARE cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$853.71 22,07% (12M)

P/E

22.42

0.38%

ROE

-352.96%

P/BV

-79.15

CAH - Cardinal Health

$234.85 55,51% (12M)

P/E

31.61

0.88%

ROE

-62.92%

P/BV

-19.89

JNJ - Johnson & Johnson

$273.41 57,54% (12M)

P/E

29.66

2.02%

ROE

24.76%

P/BV

7.34

ABBV - AbbVie

$265.97 31,23% (12M)

P/E

70.02

2.73%

ROE

-106.44%

P/BV

-74.53

MRK - Merck & Co.

$152.20 86,97% (12M)

P/E

106.68

2.45%

ROE

7.56%

P/BV

8.06

AZN - AstraZeneca

$164.95 5,00% (12M)

P/E

22.98

2.07%

ROE

20.74%

P/BV

4.77

PFE - Pfizer

$28.24 21,16% (12M)

P/E

34.62

6.54%

ROE

5.07%

P/BV

1.75

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$853.71 22,07% (12 M)

P/L

22.42

0.38%

ROE

-352.96%

P/VP

-79.15

CAH - Cardinal Health

$234.85 55,51% (12 M)

P/L

31.61

0.88%

ROE

-62.92%

P/VP

-19.89

JNJ - Johnson & Johnson

$273.41 57,54% (12 M)

P/L

29.66

2.02%

ROE

24.76%

P/VP

7.34

ABBV - AbbVie

$265.97 31,23% (12 M)

P/L

70.02

2.73%

ROE

-106.44%

P/VP

-74.53

MRK - Merck & Co.

$152.20 86,97% (12 M)

P/L

106.68

2.45%

ROE

7.56%

P/VP

8.06

AZN - AstraZeneca

$164.95 5,00% (12 M)

P/L

22.98

2.07%

ROE

20.74%

P/VP

4.77

PFE - Pfizer

$28.24 21,16% (12 M)

P/L

34.62

6.54%

ROE

5.07%

P/VP

1.75

Frequently Asked Questions

What is the price of Ultragenyx Pharmaceutical (RARE) today?

A cotação de Ultragenyx Pharmaceutical (RARE) hoje está em US$ 26.24, com uma variação de -9.89% em relação ao último ano. A cotação de Ultragenyx Pharmaceutical (RARE) iniciou o ano negociando na casa dos US$ 23.00 e hoje está em US$ 26.24. Acompanhe o gráfico de cotação em tempo real, a cotação histórica de Ultragenyx Pharmaceutical (RARE) e dados de ações do Ibovespa e mercados internacionais.

Quando Ultragenyx Pharmaceutical (RARE) paga dividendos?

Ultragenyx Pharmaceutical (RARE) não distribuiu dividendos no último ano.

Is Ultragenyx Pharmaceutical (RARE) a good investment?

Atualmente, Ultragenyx Pharmaceutical (RARE) está cotada a US$ 26.24, com um P/L de -4.54, representando um desvio de -532% em relação ao seu P/L médio histórico. No último ano, a ação apresentou uma variação de -9.89 em sua cotação e distribuiu US$ 0.00 em dividendos, resultando em um Dividend Yield de 0.00%. O retorno total do acionista foi de -9.89%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy Ultragenyx Pharmaceutical (RARE) stock?

Investir em ações de Ultragenyx Pharmaceutical (RARE) pode ser feito de duas formas: comprando a stock uma empresa estrangeira e é atrelado ao dólar.

How much would 100 shares of Ultragenyx Pharmaceutical (RARE) yield today?

A rentabilidade de Ultragenyx Pharmaceutical (RARE) foi de -8.76% no último mês, -9.89% no último ano e -67.27% nos últimos 5 anos (já considerando valorização e dividendos).

Nos últimos 12 meses, a empresa pagou um total de US$ 0.00 em dividendos, um Dividend Yield de 0.00%.

Se você quisesse comprar 100 ações de Ultragenyx Pharmaceutical (RARE) hoje, o investimento total seria de US$ 2,624.00, com base na cotação atual de US$ 26.24.

Based on historical performance, the investment would have grown to approximately:

Em 1 ano: US$ 2,364.49
Em 5 anos: US$ 858.84
Em 10 anos: US$ 2,624.00

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

RARE

Ultragenyx Pharmaceutical Inc.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment RARE

Valuation

Efficiency

Profitability

Dividends

Debt

Growth

COMPARING RARE WITH OTHER STOCK

current DY: 0.00%

5-year average DY: 0.00%

ABOUT Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc.

United States

16 years

893

PROFIT X PRICE RARE

Financial Results RARE

RARE cash flow

Asset, Revenue and Profit Growth - RARE

RARE balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

Frequently Asked Questions